Claims for Patent: 11,969,435

Summary for Patent: 11,969,435

Title:	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
Abstract:	Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor modulator (GRM) and steroidogenesis inhibitors, and by concomitant administration of a GRM and CYP3A inhibitors. The GRM may be, e.g., mifepristone; the CYP3A inhibitors or steroidogenesis inhibitors (collectively “inhibitors”) may be, e.g., ketoconazole or itraconazole. Inhibitors may cause toxicity or other serious adverse reactions; concomitant administration of inhibitors with other drugs may increase the risk of such toxicity and adverse reactions due to the inhibitors and/or the other drugs. Applicant has surprisingly found that GRMs may be administered to subjects receiving inhibitors without increasing the risk of adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole or itraconazole, providing safe concomitant administration of the GRM and ketoconazole or itraconazole. In embodiments, the GRM dose may be reduced during concomitant administration of the GRM with inhibitors.
Inventor(s):	Joseph K. Belanoff
Assignee:	Corcept Therapeutics Inc
Application Number:	US17/544,859
Patent Claims:	1. A method of treating hyperglycemia secondary to hypercortisolism in a patient with Cushing's syndrome, said patient taking an original once-daily (OD) oral dose of 1200 milligrams per day (mg/day) of mifepristone, comprising reducing said original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day wherein the patient is receiving concomitant administration of a strong CYP3A inhibitor selected from the group consisting of ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranavir, paritaprevir and voriconazole. 2. The method of claim 1, wherein said reducing comprises reducing the original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day by administering an OD oral mifepristone dose of 600 mg/day and then administering an adjusted OD oral mifepristone dose of 900 mg/day when the patient is receiving concomitant administration of a strong CYP3A inhibitor. 3. The method of claim 1, wherein said strong CYP3A inhibitor is ketoconazole. 4. The method of claim 1, wherein said strong CYP3A inhibitor is itraconazole. 5. The method of claim 1, wherein said strong CYP3A inhibitor is clarithromycin. 6. A method of treating symptoms associated with elevated cortisol levels in a patient, said patient taking an original once-daily (OD) oral dose of 1200 milligrams per day (mg/day) of mifepristone, comprising reducing said original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day wherein the patient is receiving concomitant administration of a strong CYP3A inhibitor selected from the group consisting of ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranavir, paritaprevir and voriconazole. 7. The method of claim 6, wherein said reducing comprises reducing the original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day by administering an OD oral mifepristone dose of 600 mg/day and then administering an adjusted OD oral mifepristone dose of 900 mg per day when the patient is receiving concomitant administration of a strong CYP3A inhibitor. 8. The method of claim 6, wherein said strong CYP3A inhibitor is ketoconazole. 9. The method of claim 6, wherein said strong CYP3A inhibitor is itraconazole. 10. The method of claim 6, wherein said strong CYP3A inhibitor is clarithromycin. 11. A method of treating endogenous Cushing's syndrome in a patient, said patient taking an original once-daily (OD) oral mifepristone dose of 1200 milligrams per day (mg/day), comprising reducing said original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day wherein the patient is receiving concomitant administration of a strong CYP3A inhibitor selected from the group consisting of ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranavir, paritaprevir and voriconazole. 12. The method of claim 11, wherein said reducing comprises reducing the original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day by administering an OD oral mifepristone dose of 600 mg/day and then administering an adjusted OD oral mifepristone dose of 900 mg/day when the patient is receiving concomitant administration of a strong CYP3A inhibitor. 13. The method of claim 11, wherein said strong CYP3A inhibitor is ketoconazole. 14. The method of claim 11, wherein said strong CYP3A inhibitor is itraconazole. 15. The method of claim 11, wherein said strong CYP3A inhibitor is clarithromycin. 16. A method of safely treating hyperglycemia secondary to hypercortisolism in a patient with Cushing's syndrome, said patient taking an original once-daily (OD) oral dose of 1200 milligrams per day (mg/day) of mifepristone, comprising reducing said original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day wherein the patient is receiving concomitant administration of a strong CYP3A inhibitor selected from the group consisting of ketoconazole, itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, boceprevir, clarithromycin, conivaptan, lopinavir, posaconazole, saquinavir, telaprevir, cobicistat, troleandomycin, tipranavir, paritaprevir and voriconazole. 17. The method of claim 16, wherein said reducing comprises reducing the original OD oral mifepristone dose of 1200 mg/day to an adjusted OD oral mifepristone dose of 900 mg/day by administering an OD oral mifepristone dose of 600 mg/day and then administering an adjusted OD oral mifepristone dose of 900 mg/day when the patient is receiving concomitant administration of a strong CYP3A inhibitor.